Navigation Links
Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
Date:12/7/2009

PINE BROOK, N.J., Dec. 7 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, announced today that recent animal efficacy and human safety data from the Company's Anthim® anthrax anti-toxin program were presented at the Biomedical Advanced Research and Development Authority (BARDA) Industry Day conference, December 4, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/NY01624LOGO )

In a podium presentation entitled "Advanced Development of Anthim® (ETI-204), a Highly-Effective Monoclonal Antibody for Treatment of Inhalational Anthrax: results of recent safety and efficacy studies," Dr. Leslie Casey, Vice President of Research, presented data from rabbit and primate treatment studies as well as clinical safety studies highlighting the therapeutic potential for Anthim in the treatment of anthrax disease. Using an established non-human primate treatment model, up to 79% of animals treated with a single, intravenous dose of Anthim at the onset of symptoms survived a lethal inhalational challenge with anthrax spores. All animals in this study were bacteremic at time of Anthim treatment.

The Company also reported the results of a previously conducted rabbit treatment study. A single dose of Anthim provided up to 94% survival when administered to rabbits after symptoms of disease were present. The results of these two studies are consistent with previously conducted rabbit and primate studies using Anthim and continue to show the dramatic increase in survival that Anthim can provide.

In a separate dose-escalating human clinical safety study, preliminary results show that Anthim continues to be safe and well-tolerated at doses at or above the anticipated efficacious dose in humans.

Elizabeth Posillico, PhD, President and Chief Executive Officer of Elusys, commented, "We are extremely pleased with the continued success of our Anthim program as we move into the final stages of drug development. Anthim consistently provides significant survival benefit in the treatment of anthrax infection and is safe and well-tolerated. Our drug has the potential to deliver considerable therapeutic benefit to Americans infected with anthrax in a bioterrorism emergency."

This project has been supported with federal funds from BARDA, Department of Health and Human Services (HHS), in conjunction with the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), the Department of Health and Human Services (HHS), under Contract No. HHSN272200700035C.

Anthim Background

Anthim has been extensively studied in multiple models of anthrax infection and has consistently prevented death in 70 - 100% of animals treated with a single dose of drug. Anthim shows excellent potential as an effective therapeutic for treatment of people infected or exposed to anthrax spores.

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalational anthrax following a biowarfare attack. Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA. To date, Elusys has been awarded a total of $34 million in government funding for advanced development of Anthim. Funding has been received from the NIAID, BARDA, HHS, and the Department of Defense.

About Elusys

Elusys, a private company based in Pine Brook, New Jersey, is focused on the development of antibody therapeutics for the treatment of life-threatening disease. Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit www.elusys.com.

SOURCE Elusys Therapeutics, Inc.


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
2. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
3. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
4. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
5. Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
6. Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media
7. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
8. Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting
9. Dr. Brad Vince, with Vince and Associates Clinical Research, Presents at the Exploratory Development World Congress 2009
10. Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration
11. Dr. Julian Henley MD Presents BioMatrix Lift
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Md. , March 27, 2017  ImMAGE Biotherapeutics ... its immunotherapy successfully passed early toxicology and efficacy studies. ... system to target a specific protein, MAGE A, in ... negative breast cancer. After 4 weeks ... able to show very little toxicity in a full ...
(Date:3/27/2017)... STUTTGART, Germany , March 27, 2017 /PRNewswire/ ... provide over 7,000 attendees and more than 600 ... learn, and discover opportunities and solutions that will ... - 6 April 2017 at the Messe Stuttgart, ... is the preeminent medical technology platform showcasing the ...
(Date:3/27/2017)... CHICAGO , March 27, 2017  A ... Educators (AADE) found that Medicare,s Competitive Bidding Program (CBP) ... diabetes testing supplies. The lack of choice forces beneficiaries ... can have dire health consequences. AADE,s ... reports by AADE and others pointing out the inherent ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) is pleased ... new executive director. Mr. Still was selected through a careful months-long search by the ... is known to our members, has been a part of building the RBMA since ...
(Date:3/28/2017)... ... 28, 2017 , ... Award-winning medical group Allied Anesthesia today ... board chair for Orange County health care system CalOptima Friday. CalOptima announced its ... chair Mark Refowitz’s term, which runs through June 30 of this year, until ...
(Date:3/28/2017)... Lithuania (PRWEB) , ... March 28, 2017 , ... ... technologies, today announced the release of two biometric time and attendance tracking products: ... Attendance 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition to ...
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER TOLEDO Process Analytics is ... plant water and steam. , Chlorides and sulfates cause pitting and stress corrosion ... maintenance and unplanned shutdowns. Monitoring these ions at low ppb levels has therefore ...
(Date:3/28/2017)... ... ... The Executives, Staff & Clients of MGE: Management Experts joined forces with ... Campaign at their Semi-Annual Graduation and Fundraiser Event at MGE’s St. Petersburg Office. , ... 14 internationally in literacy. Statistically, a direct relation can be a found between illiteracy ...
Breaking Medicine News(10 mins):